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A B S T R A C T
This report was produced by an Expert Working Group (EWG) consisting of UK-based researchers, veterinarians
and regulators of animal experiments with specialist knowledge of the use of animal models of spinal cord injury
(SCI). It aims to facilitate the implementation of the Three Rs (Replacement, Reduction and Refinement), with an
emphasis on refinement. Specific animal welfare issues were identified and discussed, and practical measures
proposed, with the aim of reducing animal use and suffering, reducing experimental variability, and increasing
translatability within this critically important research field.
1. Action points
The report includes a number of recommendations to improve an-
imal welfare in, and translation of, preclinical models of SCI, many of
which are highlighted in Table 1. These recommendations represent
some key points that were raised and discussed during meetings of the
EWG and during the preparation of this paper.
2. Introduction
SCI is a devastating neurological condition which impacts on the
lives of many people worldwide. For example, around 1200 people in
the UK and 17,000 in the US are paralysed each year, with a worldwide
estimated 27 million people living with the condition (Centre, N, 2019;
GBD 2016 Traumatic Brain Injury and Spinal Cord Injury Collaborators,
2019). SCI can lead not only to loss of sensory and motor function, but
also to other significant problems such as sexual, bladder and bowel
dysfunction, infections, chronic pain and cardiac and respiratory issues.
Current treatment options for SCI in humans are limited and mainly
focus on adaptive and rehabilitative therapies as well as the manage-
ment of secondary complications (Ahuja et al., 2017; Rogers and Todd,
2016). While these approaches are important, there is an urgent need
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for the development of condition-modifying or regenerative therapies
that will restore function and improve quality of life for patients.
Pre-clinical research into SCI is currently dominated by the use of
animal models. In an attempt to recapitulate many of the clinical fea-
tures of SCI, these models can involve causing significant injury, with
consequent functional losses to the animal, and have the potential to
induce high levels of suffering. This leads to strong ethical imperatives
to ensure robust implementation of the Three Rs (Replacement,
Reduction and Refinement) and to maximise the translational validity
of animal models of SCI. As it is also widely acknowledged that higher
standards of animal welfare go hand in hand with better science, this
EWG was established to identify welfare issues associated with mod-
elling SCI in animals and set out practical refinements to improve both
animal welfare and scientific quality (Poole, 1997; Baumans, 2005;
Lloyd et al., 2008; Wurbel, 2001; Everds et al., 2013; Hall et al., 2015).
Whilst SCI has been studied in a wide range of species including
rats, mice, cats, dogs, mini-pigs and non-human primates, this report
will focus on mice and rats (hereafter referred to as ‘rodents’ in the
report) since these species feature predominantly in the pre-clinical SCI
literature. The EWG comprises UK-based researchers, veterinarians and
regulators of animal experiments with expertise in SCI research, but this
document is intended to be applicable worldwide, as the requirement to
minimise pain, suffering and distress is central to international legis-
lation and guidance regarding animal experiments, e.g. in the UK, EU,
USA, Canada, Australia and China (Home Office, 2014; European
Commission, 2010; Committee for the Update of the Guide for the Care
and Use of Laboratory Animals; National Research Council, 2010;
Canadian Council on Animal Care (1993; revised), 2017; National
Health and Medical Research Council, 2013).
The EWG has set out to provide guidance for both established SCI
researchers and those new to the field, with respect to (i) selecting the
most suitable model to use in their research and, if animals are used, (ii)
improving welfare and reducing suffering, and (iii) implementing
practical steps to improve rigour and translatability, to ensure that
benefits of animal use are optimised.
3. General considerations for preclinical studies of spinal cord
injury
SCI that occurs as a result of a traumatic event (such as a motor
vehicle accident, fall, sporting injury or act of violence) is a multi-
factorial process involving a complex series of molecular and cellular
events. The initial traumatic injury causes local cellular damage which
is followed by secondary reactive processes, including ischaemia, in-
flammation, oedema, cell death, axonal degeneration, gliosis and for-
mation of scar tissue (Ahuja et al., 2017; Liverman et al., 2005;
Verhaagen and McDonald, 2012). The complexity of this secondary
injury pathology is currently not possible to recapitulate in in vitro
model systems and typically requires the use of experimental animals.
As with many areas of pre-clinical research, SCI research faces some
translational challenges. A number of the key issues regarding trans-
lation of SCI research have been summarised by Curt (Curt, 2012). All
models, by definition, have limitations and these need to be considered
and acknowledged.
3.1. In silico and in vitro approaches
Reliable in silico models for screening new potential therapeutics
for SCI, whilst being highly desirable, are not yet available due to the
lack of a comprehensive knowledge of the molecular and cellular me-
chanisms involved in SCI. However, in silico simulations are under
development, and may be useful to model certain aspects of SCI (e.g.
cervical spine loading during sporting activities) or mechanisms of ac-
tion of treatment (e.g. design of neuromodulation protocols), in order to
influence clinical and preclinical study design (Capogrosso et al., 2013;
Cazzola et al., 2017; Moraud et al., 2016; Woolfe et al., 2007; Clermont
et al., 2004; Vodovotz and Billiar, 2013). A next step could be the use of
in silico technology (e.g. non-invasive 24/7 monitoring of welfare
coupled with machine learning/artificial intelligence approaches) to
better predict humane experimental endpoints, which can help to re-
duce animal use and suffering.
There is more progress with regard to the development and use of in
vitro models to help understand the complex cellular mechanisms in-
volved in SCI (and subsequent changes) and to help identify novel
therapeutic targets. For example, in vitro technology, including using
multiple cell types and three-dimensional structures, can have sig-
nificant value (Slovinska et al., 2016; Mladinic and Nistry, 2013; Abu-
Rub, and A., and Pandit, A., 2010; Jeong et al., 2011; Shrirao et al.,
2018). These developments are in part due to ethical considerations and
the complexity and cost of in vivo models. They have also arisen be-
cause in vitro systems permit detailed and controlled examination of
specific mechanisms, including in human cells. In addition, in vitro
model systems permit screening of novel pharmacological tools and
potential therapies prior to testing in animal models, helping to reduce
Table 1
Recommendations for good practice in SCI research.
The Working Group makes the following recommendations:
1 Where cervical level injuries are necessary, injuries should be confined to one side or use a mild/moderate insult where possible.
2 Give careful consideration to the balance between translatability and harms to the animal, via discussion with animal technologists, veterinarians and the local ethics or
animal care and use committee.
3 The SCI research community should share knowledge on effective strategies to avoid adverse effects, including those listed in Table 2b, through scientific meetings,
publications and online resources.
4 Model selection should always be based on causing the least harm to the animals whilst still enabling the scientific question to be answered.
5 Provide environmental enrichment tailored to the animal's level of disability and evaluated where necessary; provide information on enrichment in publications.
6 Tailor anaesthetic protocols to the species, strain and model, in collaboration with a laboratory animal veterinarian.
7 Adequate analgesia should always be given in circumstances where animals may experience pain. Compelling scientific evidence must be provided to withhold pain relief.
8 Do not administer antibiotics routinely, but ensure they are provided if necessary.
9 Consider whether male and female animals can both be used as subjects in a given study. Bladder expression is easier in female rodents, and the risk of complications is
reduced when compared to males, but using only females introduces a sex bias. This issue should be discussed with the ethics committee on a case by case basis.
10 Humane endpoints should be defined a priori (and revised periodically in the light of ongoing expertise). Advice can be sought from the ethics committee.
11 Ensure that a structured, objective monitoring system has been tailored to each protocol, and that this is reviewed as necessary to reduce the risk of important indicators
being overlooked.
12 Plan and publish SCI research in accordance with good practice guidelines e.g. PREPARE (Planning Research and Experimental Procedures on Animals: Recommendations
for Excellence), ARRIVE (Animal Research: Reporting of In Vivo Experiments), GSPC (Gold Standard Gold Standard Publication checklist).
13 Consider working with national or international organisations or funding bodies to help develop/support training opportunities for new SCI researchers to develop the
necessary skills to perform SCI models competently and reproducibly.
Several key issues were identified during the expert working group (EWG) discussions and some recommendations were made, these are included here and high-
lighted in the text.
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and avoid animal use. It is outside the scope of this report to list all of
the currently published in vitro models of SCI; many are discussed in
the reviews cited above and in some recent papers (Shahriary et al.,
2019; Bijland et al., 2019).
Despite this progress, complete replacement of animal models of SCI
is unfortunately not currently possible. It should also be noted that
some in vitro work may also raise ethical and welfare issues if animals
are directly or indirectly used for the model system (e.g. where primary
cell cultures are generated from animal tissues), or animal serum is
required for cell or tissue culture; non-animal-derived defined alter-
natives are often available.
3.2. In vivo approaches
Where animal use can be justified on scientific grounds (e.g. fol-
lowing the harm-benefit analysis required under many national reg-
ulations), the choice of animal model should be guided not only by the
scientific objectives, but also by animal welfare considerations, with the
aim of minimising or avoiding suffering. The EWG views this as an
integral part of the process of selection of the best scientific approach.
The following sections describe issues relating to selecting animal
models of SCI, including points to consider and recommendations from
the EWG.
3.2.1. In vivo model selection
There are different ways to model SCI in animals and all approaches
have intrinsic strengths and weaknesses (Kjell and Olson, 2016; Kwon
et al., 2002; Zhang et al., 2014; Cheriyan et al., 2014). Broadly
speaking, in vivo SCI models are characterised by the spinal level where
the injury takes place (e.g. sacral, lumbar, thoracic, cervical) and the
nature of the injury or lesion (e.g. contusion, compression, transection,
hemisection). Model selection will depend on what aspect(s) of SCI is/
are being investigated. The reviews referenced above (and others)
provide information on the pros and cons of current SCI animal models
from a translational perspective and the EWG does not wish to replicate
this information here. However, at the time of writing there is com-
paratively little discussion in the literature of the animal welfare im-
plications associated with different models – yet this is an essential
consideration, bearing in mind that model selection should be de-
termined by the likelihood of providing robust, translatable data whilst
causing the minimum pain, suffering, distress or lasting harm (or se-
verity1).
The overall severity of an SCI model, with respect to the impact on
the animal, depends not only on the lesion type but also on the segment
of the cord that is lesioned and the severity of the injury at that level. In
general, lesions higher up the spine carry a higher welfare burden and,
from an ethical perspective, should require robust justification.
Complete transection at a cervical level is rarely performed because of
the impact on the animal - this causes permanent paralysis in all four
limbs, profound autonomic and cardiac deficits and difficult post-
operative care (Kjell and Olson, 2016; Lujan et al., 2018), whereas
moderate or mild bilateral contusion of the C5/6 cervical spinal cord
results in transient paresis of all four limbs and with appropriate
postoperative care can be managed effectively (James et al., 2015;
Burnside et al., 2018). Although most clinical injuries occur in the
cervical region (Kang et al., 2018), this results in a higher animal
welfare burden than similar lesions lower in the spine. Many
experiments demonstrating basic principles do not need to use cervical
injury models, e.g. for studying tissue responses to injury, or the re-
generative potential of a new therapeutic. For these studies lower level
(e.g. thoracic) lesions can be sufficient. Cervical level injuries are ty-
pically used for more advanced pre-clinical evaluations, e.g. when ef-
ficacy of a therapy has previously been demonstrated in lower level
injuries, or for assessing specific functions controlled by the cervical
cord such as respiratory function, upper limb and skilled hand function.
For these studies cervical level injuries are necessary. However, wher-
ever possible the experimenter should consider confining injuries at the
cervical level to one side or use a mild/moderate insult.
Recommendation: Where cervical level injuries are necessary, in-
juries should be confined to one side or use a mild/moderate insult
where possible.
Similarly, within one spinal region (particularly for cervical and
thoracic), there will be different burdens depending on the injury level.
For example, lesions in the high (e.g., T3) but not low (e.g., T12)
thoracic region and above may induce autonomic dysreflexia, poten-
tially affecting cardiovascular and respiratory function and the ability
to fight infection (Prüss et al., 2017). It is common to perform mild,
moderate or even severe contusions to the low (e.g., T9/10) thoracic
spinal cord, causing disability to hindlimbs without affecting re-
spiratory or upper limb function. The balance between translatability
and harms to the animal requires careful consideration, and discussion
with animal technologists, veterinarians and the local ethics or animal
care and use committee can be helpful in the decision-making process
at the project design stage.
Recommendation: Give careful consideration to the balance be-
tween translatability and harms to the animal, via discussion with an-
imal technologists, veterinarians and the local ethics or animal care and
use committee.
Strain selection is also an important factor to consider, as morpho-
logic, sensory and motor differences have been shown to exist between
commonly used strains of laboratory rat and mouse (Webb et al., 2003;
Basso et al., 2006). Indeed, rat strain selection has been reported to
influence the development of chronic central pain following SCI and
substrain differences (Sprague-Dawley rats from three different bree-
ders) have been identified in spontaneous locomotor recovery (Mills
et al., 2001; Kjell et al., 2013). Therefore, it is important to be aware
that species/strain/substrain selection may bias the interpretation of
true efficacy of a therapeutic tested with a view to successful translation
to patients.
With regard to dorsal root crush models, one EWG member has
found that ‘docile’ strains of rat (e.g. Lewis and Sprague Dawley) have a
lower risk of autotomy (denervation-induced self biting; M. Andrews,
personal communication; January 2018). It is important to discuss
strain selection with local experts (animal care staff, veterinarians and
local ethics or animal care and use committees) as well as with ex-
perienced SCI researchers. Any welfare concerns that arise from the use
of a specific species or strain, and other strategies to avoid adverse
effects and reduce severity, should be communicated to other groups, to
help them prevent avoidable harms.
Recommendation: The SCI research community should share
knowledge on effective strategies to avoid adverse effects, including
those listed in Table 2b, through scientific meetings, publications and
online resources.
Ultimately, model choice should be decided on the basis that the
least invasive (causes the least welfare impact on the individual animal)
approach is used that enables the scientific question to be answered.
Key to this process is a clear a priori definition of the scientific
question being asked coupled with a detailed understanding of the
strengths and limitations of the various models that are available. The
EWG recommend that, within the context of the experimental question,
model selection should be based on the following principles:
(i) Selecting the type and location of lesion that has least welfare/
1 UK and EU legislation regulating animal use includes severity categories
ranging from non-recovery (procedures carried out under general anaesthetic
without recovery) through mild and moderate to severe (similar categorisation
systems are used in the USA and Canada). Injury intensity within SCI research
can also be classified as mild, moderate or severe, but a ‘mild’ injury to the
spinal cord with respect to the nature and degree of injury will almost certainly
cause more than ‘mild’ suffering, as defined by legislation, to the animal.
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physical impact,
(ii) Considering partial as opposed to complete lesions if possible,
(iii) Researching and consulting on species and strains that will recover
best from the proposed protocol.
Recommendation: Model selection should always be based on
causing the least harm to the animals whilst still enabling the scientific
question to be answered.
4. Potential adverse effects and how these can be refined
As well as addressing and refining harms due to experimental pro-
cedures and their after-effects, a useful complementary approach to
reducing suffering is to set out the whole life experience of the animal
and consider how each potentially painful or distressing event could be
refined. The overall impact should be a significant reduction in severity.
The overarching principle of this approach is the ‘accumulation of
marginal gains’, in which each individual refinement may not make a
significant difference in itself, but when implemented all together the
effect may be that a procedure is considerably less severe to each an-
imal (Lilley and Jennings, 2013).
Tables 2a and 2b set out potential adverse effects that may be ex-
perienced by animals used in SCI studies, with suggested ways of
ameliorating pain or distress in line with the ‘accumulation of marginal
gains’ principle. Table 2a lists general adverse effects associated with
surgery and behavioural training, and Table 2b sets out model-specific
adverse effects. The EWG understands that not all of the suggested re-
finements will be feasible within every project, and additional text to
supplement the Tables is set out below.
4.1. Housing, husbandry and care
Ramsey and colleagues have published a set of proposals for the
care of rats with high-thoracic SCI (T3 complete transection), based on
many years of experience with this model (Ramsey et al., 2010). The
EWG recommends this paper as an excellent guide to refining housing
and care for rodents following high thoracic SCI, although the princi-
ples it describes are applicable to other severe SCI models. Specifically,
they focus on the lifetime experience of the animals, including:
• Acclimatisation (at least one week if animals are shipped in from
external suppliers);• Habituation to the post-operative diet before surgery;• Housing refinements, e.g. low-reaching water bottles, matting on
the floor to help mobility, refuges and social housing;• Refined post-operative care, including optimal analgesia and fre-
quent cage change to avoid pressure sores.
Table 2a
General adverse effects and refinements.
Potential adverse effect How this may be refined
Discomfort or distress due to capture, handling and restraint Catch and restrain animals using the most refined approach for the species; for example, catching mice by
cupping in the hands, or in their home cage tunnel, instead of by the tail. Catching in the hands, or tunnel, is
less aversive and induces less anxiety (Gouveia and Hurst, 2017; Gouveia and Hurst, 2013; Hurst and West,
2010). Similarly, rats should never be picked up by the tail. Following surgery, ensure that extra care is taken
when handling animals to minimise discomfort and ensure that further damage does not occur. Handling
should be gentle and empathetic throughout the animals' lives, to reduce distress. Habituation to handling
techniques, especially in rats, will reduce anxiety and stress.
Stress during behavioural assessment training Habituate animals to handling and behavioural testing methods prior to SCI surgery. This is essential to reduce
stress following surgery, and to ensure animals unable to learn the behavioural tests will not be operated on.
The acclimatisation period will depend on the test and apparatus, as well as the species and strain of animal,
and some individuals may require more training than others.
Pain and infection risk due to surgery Research and use the most effective and least aversive anaesthetic agent that is compatible with the scientific
objectives.
Provide appropriate peri- and post-operative analgesia, using a suitable multi-modal protocol, e.g. carprofen/
buprenorphine.
Use a regulated (homeothermic) system to maintain the body temperature of the animal during procedures
and recovery.
Use aseptic techniques: the EWG recommends working to standards set out in the Laboratory Animal Science
Association (LASA) guidance on aseptic surgical technique (Jennings and Berdoy, 2016); antibiotics should
not be used routinely.
Ensure optimal surgical approach, and handle tissues gently during surgery, so as to minimise unwanted tissue
damage.
Ensure that the surgeon is adequately trained and competent; record individual surgeon-related postoperative
outcomes including animal behaviour observations and analgesia requirements. Review these ‘benchmark’
data regularly.
Discomfort or distress during recovery and initial post-operative
period
Keep animals homeothermic during the initial surgical recovery period, and beyond if shown to be beneficial.
Warmed, quiet and darkened recovery cabinets (e.g. with air controllably warmed to 26 °C) can be useful
(Keijer et al., 2019). Less preferred are heated mats or lamps: care must be taken to ensure that temperature is
adequately controlled and not too high, with heat uniformly distributed, and ensuring that animals are
sufficiently mobile to be able to move away to a cooler zone.
Avoid excessive handling for 24 h post-surgery, e.g. no more than twice daily.
Regularly review postoperative monitoring protocols, including use of structured recording systems such as
score sheets.
Hunger and/or thirst due to difficulty accessing food and water
during the recovery period
Provide moistened standard chow in accessible containers on the cage floor and soft/liquid nutrition until
animals can access food independently; hand feed in the interim if necessary (e.g. by syringe) (Ramsey et al.,
2010).
Take proactive measures to prevent dehydration, e.g. by using water bottles with long spouts and/or providing
hydrogel. If necessary, rehydrate with sub-cutaneous injections of saline pre-warmed to body temperature.
Monitor body weight and food/water intake daily during recovery until body weight returns to the pre-
operative value. Pay attention to any deviation from expected values/rate of recovery, monitoring the rate of
change and duration of any plateaus as indicators of the quality of recovery.
Give supplementary fluids (e.g. subcutaneous saline) to counter weight loss, which is principally due to
dehydration. For example, if a rat loses 10 g in body weight acutely, supplement with 10 ml prewarmed saline.
List of general adverse effects that animals may experience in a SCI study and approaches to ameliorate these.
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Besides implementing tailored husbandry refinements such as the
above, environmental enrichment is important for animals used in SCI
protocols and should be provided wherever possible. There are two
main reasons for this.
First, it is commonly acknowledged that environmental enrichment
improves animal welfare. For example, recent versions of legislation,
guidelines and codes of practice relating to laboratory animal use em-
phasise the importance of a stimulating environment to encourage ap-
propriate natural behaviours (European Commission, 2010; National
Research Council, 2009; CIOMS/ICLASInternational Guiding Principles
for Biomedical Research, 2012). These can be facilitated by including
group housing for social animals and environmental enrichment such as
nesting material, refuges and chew blocks for rodents.
Second, environmental enrichment may aid recovery, by stimula-
tion of locomotor activity, in some animal models (Faralli et al., 2013;
Vachon et al., 2013; Lankhorst et al., 2001). Indeed, it may be argued
that enriched caging is more reflective of human clinical practice,
where physiotherapy will be used to promote recovery for patients.
Enrichment should be tailored to the animal's level of disability, eval-
uated where necessary (e.g. if an item is new, or there are questions as
to benefit) and clearly reported in publications.
Recommendation: Provide environmental enrichment tailored to
the animal's level of disability and evaluated where necessary; provide
information on enrichment in publications.
4.2. Surgery
Anaesthetic protocols and agents should be chosen in collaboration
with a laboratory animal veterinarian and tailored to the species (and
possibly the strain) being used. The duration of anaesthesia should
generally be minimised, to facilitate recovery; inhalational anaesthesia
(e.g. isoflurane) is preferred over longer-lasting injectable anaesthestics
by some laboratories for improved post-operative recovery after cer-
vical contusion injury (L Moon and E Bradbury labs, personal com-
munication; February 2019) or long surgeries. In addition, the choice of
anaesthetic agent may be influenced by the surgical equipment being
used to stabilize animals for surgery (masks for inhalation of volatile
agents may be too large or cumbersome in some experimental set-ups;
some EWG members use reversible injectable anaesthetics for this
reason such as ketamine combined with medetomidine (Domitor) that
can be reversed by atipamezole (Antisedan). Some gaseous agents are
aversive to some species and strains, which can cause distress; the at-
tending veterinarian should be able to advise on preferable gaseous
anaesthetics if these are used.
Recommendation: Tailor anaesthetic protocols to the species, strain
and model, in collaboration with a laboratory animal veterinarian.
During and following surgery, mice and rats should be kept warm in
order to mitigate the risk of hypothermia which can slow recovery and
is a major risk factor for post-surgical mortality (Pottie et al., 2007;
Flecknell, 2009). Incubators with regulated warm air systems (e.g.
26 °C) designed for animal recovery are preferred over heating blankets
placed under the cage (Keijer et al., 2019). Following recovery, animals
should be returned to their stable pairs, or groups, unless there are
compelling scientific or animal welfare reasons for single housing. In
cases of single housing, additional enrichment or stimulation should be
provided to the animals.
4.3. Analgesia
Provision of pain-relieving drugs should be the default position for
all potentially painful experimental procedures, unless there is com-
pelling scientific justification otherwise. This is a legal requirement in
the EU and UK. SCI is clearly an example of an experimental paradigm
that has the potential to cause significant pain for laboratory animals.
There are two aspects to the pain: that induced by the surgical proce-
dure, and that which may arise from the SCI itself. The EWG re-
commends that provision of analgesia should be the default position
during and after surgical SCI, unless specific evidence for its exclusion
can be given. Multi-model analgesia should be considered including
opioid (e.g. buprenorphine), non-steroidal anti-inflammatory drugs
Table 2b
SCI model-specific adverse effects and refinement.
Potential adverse effect Model(s) where relevant How this may be refined
Impaired bladder function Transection
Contusion
Perform manual bladder expression with sufficient regularity (e.g. twice a day) to reduce
the risk of bladder infection and discomfort, and wash genitals twice daily.
Urine scalding/urinary tract infection Transection
Contusion
Even when animals can urinate normally, hind limb paralysis can cause problems. Use
appropriate absorbent litter to reduce the incidence and impact of urine scalding, e.g. a
sheet of 140 gsm white crepe paper on top of standard litter such as Lignocel premium
hygienic animal bedding. Alternatively add fenestrated matting with bedding above
(Ramsey et al., 2010).
Constipation Transection
Contusion
Monitor animals carefully to enable early recognition of changes in bowel function.
Mineral oil can be added to food and fluids to aid bowel function. A gentle enema of warm
saline may also be beneficial.
Impaired locomotion Transection
Contusion
Provide plastic mesh or corrugated card on the cage floor to help animals move around the
cage (always in conjunction with appropriate litter and nesting material, as a grid floor
without litter is not appropriate) (Ramsey et al., 2010).
Autotomy Contusion
Compression
Hemisection
Dorsal rhizotomy
Strain selection may reduce incidence of autotomy (e.g. in EWG experience, Hooded Lister
rats tend to have higher risk than Sprague Dawley and Lewis).
Ensure that monitoring is adequate to rapidly identify animals at risk so that humane
endpoints can be implemented.
Consider prophylactic treatment using amitriptyline for models where autotomy is
common (Sotocinal et al., 2011; Seltzer et al., 1989).
Difficulty feeding in the acute post-injury
phase
All surgical models - particularly
injuries at the cervical level
Provide moistened standard chow, fluid rich fruit (e.g. grapes/melon) or liquid/semi solid
nutrition, (e.g. baby food) in the cage, with hand feeding via syringe if necessary.
Introduce supplementary food before surgery so that animals recognise and are prepared
to take the post-surgery diet.
Problems with hydration All surgical models Facilitate access to water by providing water bottles with longer spouts or provide
hydration gel (e.g. HydroGel). Administer subcutaneous saline if necessary.
Pain associated with the model, i.e.
following recovery from surgery
All surgical models Consider using pain face/grimace scales to help identify acute pain, as part of a tailored
welfare assessment protocol (Descovich et al., 2017).
Use appropriate analgesia (e.g. gabapentin) if neuropathic pain develops following
surgery (Baastrup et al., 2018).
List of SCI model specific adverse effects and approaches to ameliorate these.
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(NSAID; e.g. carprofen, meloxicam) and local anaesthetics (e.g. bupi-
vicaine) (Redaelli et al., 2019). Analgesics for neuropathic pain such as
gabapentin or pregabalin could also be provided; indeed, pregabalin
has been shown to reduce mechanical hypersensitivity following con-
tusion injury in rats (Baastrup et al., 2018). The attending veterinarian
should be consulted when selecting the most appropriate analgesia
regimen. Without analgesia, uncontrolled pain will cause increased
variability between animals (Carbone, 2011; Carbone, 2017). Assess-
ment of pain in SCI animals can be challenging, especially if postural
signs are lost due to the injury. The recent development of pain-face/
grimace scales in rats, mice and a range of other mammals may provide
a useful tool, if properly applied, to allow the assessment of acute pain
as part of an integrated welfare assessment process (Sotocinal et al.,
2011; Langford et al., 2010; Descovich et al., 2017).
Recommendation: Adequate analgesia should always be given in
circumstances where animals may experience pain. Compelling scien-
tific evidence must be provided to withhold pain relief.
In studies using dorsal root injury (rhizotomy, crush, avulsion;
where the risk of autotomy can be high), consideration should be given
to prophylactic treatment with amitriptyline which can decrease self-
mutilation (Abad et al., 1989; Navarro et al., 1994). Indeed, ami-
triptyline is typically given to humans after avulsion injury and argu-
ably, animals should be treated in the same way as humans in order for
a model to have face validity (although potential interactions of pain-
relieving analgesics with any therapeutic intervention should be con-
sidered) (Bruxelle et al., 1988).
4.4. Antibiotics
Surgical asepsis should negate the need for antibiotic use in the
immediate post-surgical period, unless foreign material implants are
being used. However, in SCI surgery there is a risk of bladder infection
if animals cannot urinate spontaneously. Antibiotic use should be
carefully considered, since long-term use of broad-spectrum antibiotics
in large numbers of animals could lead to the development of antibiotic
resistant bacteria, which would have broader implications and may
impact upon all housed animals within research facilities (van den
Bogaard and Stobberingh, 2000). Antibiotics can also induce gut dys-
biosis, and it has been shown that an improved microbiome leads to
better recovery after SCI (Kigerl et al., 2016). Urinalysis strips are
available that permit early detection of urinary tract infection (UTI) and
could be used to prompt antibiotic use only when required (Paquignon
et al., 1993; Siska et al., 2016). Also, antibiotics can cause a variety of
side effects and potentially interfere with the pharmacokinetics of
therapeutic agents under investigation (Morris, 1995). Anecdotally,
bladder infections are much rarer in rats with ‘moderate’ cervical
contusion than ‘moderate’ thoracic contusions and antibiotics do not
need to be used routinely after cervical contusion in rats. The attending
veterinarian should be able to advise on the most appropriate approach
to deal with the risk of infection, while still being able to achieve the
scientific outcome.
Recommendation: Do not administer antibiotics routinely, but en-
sure they are provided if necessary.
4.5. Bladder function
Depending on the nature, spinal level and severity of SCI injury,
bladder function can be impaired. It is important to ensure that urine is
voided adequately with sufficient frequency until spontaneous voiding
is re-established. Normal micturition in rats requires spinal and su-
praspinal circuitry to mediate contraction of the bladder detrusor and
co-ordinated activation of the external urethral sphincter (Pikov and
Wrathall, 2001). In T3 complete transection models and moderate T9/
10 contusions (but not bilateral C5/6 contusions), for example, the
bladder needs to be manually expressed 3–4 times a day during the
initial post-surgery period, reducing to twice a day in models where
reflexive micturition returns (Ramsey et al., 2010). It should be noted
that bladder function recovery can vary between species - for example,
rats with T9/10 contusions typically recover bladder function after
1–2 weeks. In mice with the same injury bladder function never re-
covers and they need manual bladder expression throughout the
duration of the study. One technique to achieve manual emptying is
shown in a recent Journal of Visualised Experiments (JOVE) article
(Krishna et al., 2013).
During our discussions, the EWG suggested that bladder expression
was easier in female rodents, due to the relative ease of bladder ex-
pression and lower risk of bladder infections and other complications
(e.g. urethral blockages) when compared to males. This does however,
raise the issue of the introduction of sex bias into SCI pre-clinical re-
search as well as a potential issue with translation since around 80% of
new cases of SCI occur in males (Wald and Wu, 2010; National Spinal
Cord Injury Statistical Center: Facts and Figures at a Glance, 2016). This
issue (animal welfare considerations in potential conflict with transla-
tion) should be evaluated on a case by case basis.
Recommendation: Consider whether male and female animals can
both be used as subjects in a given study. Bladder expression is easier in
female rodents, and the risk of complications is reduced when com-
pared to males, but using only females introduces a sex bias. This issue
should be discussed with the ethics committee on a case by case basis.
4.6. Pilot studies
Pilot studies are a useful way to evaluate the welfare impact of a
particular procedure or intervention where prior knowledge is lacking.
In particular, pilot studies can be used to evaluate a refinement of an
existing procedure or model, for example the use of an alternative
surgical approach or home-cage based behavioural assessment.
However, although animals subsequently used in a full study should
benefit, pilot studies demonstrating that a particular refinement is ef-
fective also have the potential to cause suffering and will require ad-
ditional animal use. They should therefore be subject to a harm-benefit
assessment.
4.7. Humane endpoints
A ‘humane endpoint’ can be defined as the point at which an animal's
pain and/or distress is terminated, minimised or reduced, by taking
actions such as killing the animal humanely, ending the procedure or
giving treatment to alleviate suffering (see http://www.humane-
endpoints.info). Humane endpoints should be specific and tailored to
each study and will depend upon factors including the aims of the study
and the stage at which sufficient data are obtained. The scientific
endpoint may correspond to the humane (welfare) endpoint – i.e. there
is no benefit to keeping the animal alive any longer and therefore the
experiment should end, usually by humanely killing the animal; in the
context of SCI this is usually for the purpose of completing histological
or other tissue analyses. Sometimes a predetermined ‘severity limit’ has
been set, such that the adverse welfare impact of the experiment cannot
ethically or legally exceed a predefined level on ethical grounds. In
these cases, local ethics or animal care and use committees and project
evaluators may have input into defining humane endpoints.
In all other cases, experiments using living animals should have
endpoints set which are sufficient to achieve the scientific endpoint but
represent the most humane way to do this. Suggested humane end-
points for rodent models of SCI are given in Table 3; note that specific
humane endpoints should be defined for each model, taking into ac-
count species/strain considerations.
The EWG believes that the use of early humane endpoints is an
ethical obligation when using animals in SCI research and recommends
that a dedicated welfare assessment system is used to help achieve
objective and refined humane end points (see section 6 and Table 3).
This may be a structured, objective recording system or a list of clinical
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signs and interventions. These require careful design and staff training
and familiarisation. Attentive monitoring should be employed, at a
frequency that reflects the time course and severity of the model so that
suffering can be minimised, and humane endpoints effectively im-
plemented.
There is an inherent dilemma associated with defining and im-
plementing humane endpoints in potentially severe procedures. A bal-
ance must be reached between reducing the suffering of an individual
animal against the need to conduct the same procedure on an additional
animal. This ‘tension’ between the principles of refinement and reduc-
tion should be discussed by the ethics committee.
Recommendation: Humane endpoints should be defined a priori
(and revised periodically in the light of ongoing expertise). Advice can
be sought from the ethics committee.
Once a humane or scientific endpoint has been reached, it is es-
sential to use the most humane killing method possible that is compa-
tible with any postmortem tissue collection or histology requirements.
It should be noted that there is considerable debate about the huma-
neness of some killing techniques (e.g. the use of CO2), and the EWG
recommends that researchers should keep up to date with the literature
and consult animal technologists and veterinarians with respect to
current approaches (European Commission, 2012).
5. Assessing animal wellbeing, pain, suffering or distress in SCI
studies
In order to assess the welfare status of animals used in any scientific
study, it is essential to understand what ‘normal’ behaviour and baseline
physiological parameters are for the species, strain, sex and life stage of
the animal being studied, and possibly for the individual animal. This
enables rapid recognition of indicators of discomfort, pain or distress
associated with the model, as well as detection of any unforeseen ad-
verse effects, so that all of these can be ameliorated.
Post-operative care is critical to successful management of animal
welfare in SCI studies. We recommend that post-operative care is tai-
lored for the species, strain and model being used, taking into account
the natural history of the model –intensive post-operative care is par-
ticularly important for some severe injury models and requires a sig-
nificant commitment and pro-active monitoring by the principal post-
operative care givers. This will require a team approach, with input
from the researcher(s), animal technologists, attending veterinarian
and ethics or animal care and use committee (Hawkins et al., 2011;
European Commission, 2013; European Commission, 2012). An ex-
ample of such a plan is included in Table 4.
Some groups have developed structured, objective recording sys-
tems that identify specific potential clinical signs and assign each of
them scores that reflect their severity. An example monitoring sheet is
shown in Table 5. Whichever approach is used, it is critical that welfare
assessment is tailored to the species, strain and model being used, that
staff are empathetic and competent and that a clear action plan is in
place to alleviate suffering if necessary (i.e. if a humane endpoint is
approached).
Recommendation: Ensure that a structured, objective monitoring
system has been tailored to each protocol, and that this is reviewed as
necessary to reduce the risk of important indicators being overlooked.
6. Strategies to improve the rigour and translatability of SCI
research
This section sets out some approaches to help augment the benefits
associated with in vivo SCI research projects, which the EWG believes is
especially important given the potential severity of some protocols.
6.1. Experimental design and the potential for reduction
It is rare for power calculations to be reported in SCI publications, as
is currently also the case for most published animal research, although
this may be improving (Watzlawick et al., 2016; Macleod et al., 2015;
Cressey, 2016). This raises the possibility that experiments have pre-
viously been underpowered (using too few animals, wasting animals
and producing unreliable data) or overpowered (using too many ani-
mals and causing avoidable suffering). Additionally, a recent study into
the reporting standards of animal research in critical care journals in-
dicated that ‘ethical quality’ (defined by the authors as the reported use
of analgesia, anaesthesia, welfare assessment and methods of humane
killing) was poor (Bara and Joffe, 2014). Clearly, all research should be
conducted and reported in a manner that upholds high ethical and
scientific standards. This is especially important in areas such as SCI
research, where there is the potential for severe suffering of laboratory
animals and a pressing clinical need. Good practice guidelines are
available for planning and reporting studies that involve experimental
animals, and this EWG recommends that SCI researchers adopt the
Table 3
Humane endpoints.
Clinical sign / welfare issue Threshold for humane endpoint
Autotomy 1 phalange removed from 2 or more digits or 2 or more phalanges of 1 digit removed or paw becomes swollen and painful.
Pain/distress Any unexpected pain/distress (not within the normal experience of the model) that does not resolve when treated with appropriate analgesia. For
example, more than one of the following signs of severe pain and distress persisting for 1 h following administration of additional analgesia:
• copious, persistent oculo-nasal discharge• unprovoked vocalisation• marked piloerection/staring coat
Body weight Weight loss of > 20% unless other adverse welfare indicators are absent and weight loss is expected to be temporary.
Food intake > 70% reduction in food intake, despite proactive support/hand feeding, for more than 72 h.
Bladder function Persistent inability to urinate in models where bladder function is expected to recover (e.g. following moderate thoracic contusion injury in rats,
reflexive bladder emptying should be restored within 2 weeks post injury).
Bladder rupture following manual expression.
Bladder infection that does not respond to treatment.
Paralysis In models where partial or full recovery of movement is expected, persistent paralysis/lack of mobility/inability to bear weight. (e.g. following
bilateral moderate contusion injury, weight bearing should be restored within 2 weeks; in dorsal root crush models, only transient weakness that
resolves within 7 days is expected; in severe unilateral spinal cord injuries persistent paralysis is expected on the affected side).
Lethargy/apathy Animals that do not respond to handling.
Wound healing Post-surgical wounds that do not heal within expected timelines.
Wound dehiscence that does not resolve following a single attempt to repair the wound.
Infection following surgery that does not respond to veterinary intervention.
Wound scratching Severe scratching that persists and the skin lesion is not reduced in size by 50% by 5 days.
List of clinical signs/welfare issues that, depending on the nature of the SCI study, may represent thresholds for intervention in order to prevent unnecessary suffering
or distress.
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principles of these guidelines when designing and reporting their stu-
dies (Smith et al., 2018; Landis et al., 2012; Hooijmans et al., 2010;
Kilkenny et al., 2010; ILARGuidance for the Description of Animal
Research in Scientific Publications, 2014).
Recommendation: Plan and publish SCI research in accordance with
good practice guidelines e.g. PREPARE (Planning Research and
Experimental Procedures on Animals: Recommendations for
Excellence), ARRIVE (Animal Research: Reporting of In Vivo
Experiments), GSPC (Gold Standard Gold Standard Publication check-
list).
6.2. Training
Gaining the surgical skills to perform SCI reproducibly in animals is
not trivial and the EWG recognises the importance of continuity of staff
and the requirement for training opportunities for new/replacement
staff in this field. Formal training courses are currently limited in
number and include a USA university training course (Ohio [http://sci.
osu.edu/]) and the European Neurotrauma School [https://www.
spinal-research.org/neurotrauma-summer-school]. Most researchers
are trained through cascade training (i.e. where the principal in-
vestigator receives training and then passes the training on to their
colleagues and research staff). Lack of training provision is problematic
with regard to reproducibility of SCI research and raises a challenging
ethical issue; poorly trained researchers cannot perform experiments
robustly, which may result in unreliable data, avoidable suffering and
wasted animals. On the other hand, using live animals for training re-
quires stringent ethical consideration and must be specifically justified
Table 4
Example of expected outcomes and post-operative care: Cervical Level Bilateral Contusion Injury in rats (Adapted from a Post-Operative care protocol provided by
the Bradbury Laboratory).
Time Expected outcomes Post-operative care
0-24 h • Animals are expected to be laterally recumbent and lack full ability to
groom effectively. There will be partial paralysis to forelimbs and
hindlimbs.• Animals will appear sedate and may display signs of pain/distress such as
porphyrin secretion from the nose/eyes or vocalisation when touched.
• Following the return of animals to the cage from the recovery incubator,
inspect them multiple times during the day and evening to ensure food and
hydration gel is within easy reach.• The morning of the day following surgery:
o As standard, administer 5 mg/kg Carprieve analgesic subcutaneously. This is
normally adequate pain relief, but a stronger analgesic should be administered
if required (Buprenorphine, 0.03 mg/kg, subcutaneously).
o Deliver 5 ml saline subcutaneously.
o Animals should be placed in freshly lined cages, with some soft enrichment
bedding added into the cage, alongside non-standard dietary provisions.• Animals should be inspected again every 3 h on the first day following surgery,
or more frequently if any animals are displaying signs of pain in case additional
analgesic is required.• Food and hydration gel should be placed within reach.• In the evening on the day following surgery animals will be offered recovery gel/
peanut butter mixed with water from a syringe.
24 h-4 days • Animals are expected to be laterally recumbent and lack full ability to
groom effectively. There will be partial paralysis to forelimbs and
hindlimbs.• Animals will appear sedate and may display signs of pain/distress such as
porphyrin secretion from the nose/eyes or vocalisation when touched.
• At 48 h 5 mg/kg Carprieve analgesic should be administered. Analgesic beyond
this will be administered in consultation with the NVS.• Animals may be bathed (and dried fully to prevent temperature loss) as
necessary.• Hydration state should be ascertained via cutaneous pinch and saline delivered
for 3 days subcutaneously as standard, and after this if required.• Every 3–4 h during the day, and evening (if required), animals will be monitored
and food and hydration gel placed within easy reach of each animal.• Animals will be offered DietGel Boost/ peanut butter mixed with water from a
syringe.• Body weight should be measured daily and recorded until animals gain, and
begin to plateau, in weight. Any animal which loses > 20% preoperative weight
is has reached an end-point and must be humanely euthanized via schedule 1 or
perfusion for tissue collection and removed from experimental study. Any
animals which lose 10% bodyweight will be intensively hand-fed every 4 h
during the day and evening and supplementary fluids given orally or
subcutaneously.• Typically animals will remain housed on absorbent cage lining, with increasing
quantities of sawdust and enrichment bedding added daily and fresh cage lining
applied where necessary.
4-7 days • Condition of animals should improve during this period. Animals may
appear laterally recumbent or sedate at rest but are able to locomote in the
cage to access food and water. The ability to groom increases. There will
be partial paralysis to forelimbs and hindlimbs. Full weight bearing is
delayed until the 2nd week post surgery in most instances.
• Increasing quantities of sawdust and enrichment bedding should be added to
the cage on a daily basis towards resumption of normal husbandry conditions.• Cages may be removed from the cage holding incubator chamber and returned to
the holding room as deemed appropriate by the experimenter, unless there is
cause for concern.• Food and hydration gel is added in-cage until animals can obviously reach
hoppers and animals offered DietGel Boost/ peanut butter mixed with water from
a syringe if bodyweight has not increased.• Animals should be inspected a minimum of twice daily.
7 days+ • Animals are able to locomote in the cage to access food and water and
groom with much greater efficacy. There will be partial paralysis to
forelimbs and hindlimbs. Full weight bearing is delayed until the 2nd
week post surgery in most instances.
• Standard husbandry conditions are restored and animals returned to the
normal cage-holding room.• Food and hydration gel is added in-cage until animals can easily reach hoppers
and animals offered DietGel Boost/ peanut butter mixed with water from a
syringe until bodyweight increases if required.• Throughout the experiment, animals will be monitored for potential adverse
events listed in the Project License.
Model specific methods of welfare monitoring are important in order to identify welfare issues and apply appropriate care. This is an example of a post-operative care
plan for animals following cervical level bilateral contusion injury.
E. Lilley, et al. Experimental Neurology 328 (2020) 113273
8
Ta
bl
e5
Ex
am
ple
so
fi
nd
ica
tor
sf
or
we
lfa
re
as
ses
sm
en
ts
co
rin
gs
ys
tem
sf
or
SC
Is
tu
die
su
sin
gm
ice
or
rat
s(
ad
ap
ted
fro
m
sco
re
sy
ste
m
pr
ov
ide
d
by
S.
Mc
Er
lan
e,
UB
C,
Ca
na
da
).
He
alt
h
ob
ser
va
tio
ns
Sc
or
e0
Sc
or
e1
Sc
or
e2
Sc
or
e3
Sc
or
e4
Sc
or
e5
Re
sp
on
se
Co
nt
inu
em
on
ito
rin
ga
s
pe
rp
ro
toc
ol;
pr
ov
ide
su
pp
or
tiv
ec
are
ba
sed
on
cli
nic
al
sig
ns
Mo
nit
or
at
lea
st
on
ce
da
y;
pr
ov
ide
su
pp
or
tiv
ec
are
ba
sed
on
cli
nic
al
sig
ns
Mo
nit
or
at
lea
st
tw
ice
a
da
y;
pr
ov
ide
su
pp
or
tiv
e
ca
re
ba
sed
on
cli
nic
al
sig
ns
Inc
rea
se
mo
nit
or
ing
fre
qu
en
cy
to
at
lea
st
th
ree
tim
es
ad
ay
;p
ro
vid
es
up
po
rti
ve
ca
re
ba
sed
on
cli
nic
al
sig
ns
Inc
rea
se
mo
nit
or
ing
fre
qu
en
cy
to
at
lea
st
fou
rt
im
es
ad
ay
;p
ro
vid
ee
xte
ns
ive
su
pp
or
tiv
ec
are
ba
sed
on
cli
nic
al
sig
ns
Im
me
dia
te
eu
th
an
as
ia
un
les
s
Ve
ter
ina
ria
nh
as
giv
en
ap
pr
ov
al
to
co
nt
inu
es
up
po
rti
ve
ca
re
Bo
dy
W
eig
ht
/B
od
y
co
nd
iti
on
sco
rin
g
(B
SC
)
≥
Pr
esu
rg
ica
lw
eig
ht
↓w
eig
ht
by
<
5%
↓w
eig
ht
by
5–
9%
↓w
eig
ht
by
10
–1
4%
↓w
eig
ht
by
15
–1
9%
(IT
)
↓w
eig
ht
by
≥
20
%
(IE
)
Be
ha
vio
r:
Ac
tiv
ity
Ga
it
No
rm
al
mo
bil
ity
ab
ov
e
an
dc
on
tra
lat
era
lt
oi
nju
ry
BA
R
(B
rig
ht
,A
ler
t,
Re
sp
on
siv
e)
QA
R
(Q
uie
t,
Al
ert
,
Re
sp
on
siv
e)
Sli
gh
tly
slo
w
mo
vin
g;
sti
ll
int
ere
ste
di
ne
nv
iro
nm
en
t,
so
cia
la
nd
ale
rt
Le
ss
int
ere
ste
di
nt
he
en
vir
on
me
nt
,
int
era
cts
les
sw
ith
ca
ge
ma
tes
,d
isr
eg
ard
s
ob
ser
ve
r;
wh
en
nu
dg
ed
,r
elu
cta
nt
ly
mo
ve
s
aw
ay
.O
cc
as
ion
al
ab
no
rm
al
ga
it
e.g
.
lim
pin
go
r“
tip
-to
ed
”g
ait
on
“n
or
ma
l”
leg
s.
Iso
lat
ed
fro
m
ca
ge
ma
tes
,m
ini
ma
lly
ac
tiv
e;
do
es
no
tr
ea
dil
ym
ov
ew
he
nc
ag
e
dis
tu
rb
ed
.W
he
n
nu
dg
ed
,r
elu
cta
nt
ly
mo
ve
s.
Fr
eq
ue
nt
lim
pin
go
r“
tip
-to
ed
”g
ait
on
“n
or
ma
l”
leg
s.
(IT
)
Im
mo
bil
eo
rh
yp
era
cti
ve
;n
ot
mo
vin
g
wh
en
nu
dg
ed
;a
nim
al
ca
nn
ot
rig
ht
its
elf
.D
rag
gin
go
rn
on
-w
eig
ht
be
ari
ng
on
“n
or
ma
l”
leg
s(
IE
)
Ap
pe
ara
nc
e:
Gr
oo
mi
ng
/F
ur
Po
stu
re/
Po
rp
hy
rin
No
rm
al
Mi
ld
po
rp
hy
rin
aro
un
d
ey
es
bu
tg
ro
om
ed
aw
ay
Pil
oe
rec
tio
n(
<
10
%
of
bo
dy
);
Mi
ld
po
rp
hy
rin
aro
un
de
ye
s/n
os
tri
ls;
no
t
gr
oo
me
da
wa
y
Pil
oe
rec
tio
n(
25
%
of
bo
dy
e.g
.b
as
eo
f
ne
ck
)a
nd
du
ll
fur
(n
ot
sh
iny
or
sm
oo
th
).
Sli
gh
th
un
ch
ing
in
ba
ck
Mo
de
rat
ep
or
ph
yr
in
aro
un
de
ye
sa
nd
no
str
ils
.
Pil
oe
rec
tio
n(
50
%
of
bo
dy
),
fur
ma
tte
d
an
du
n-g
ro
om
ed
.
Se
ve
re
hu
nc
hin
gi
nb
ac
ke
ve
nw
he
n
wa
lki
ng
.
Mo
de
rat
ep
or
ph
yr
in
aro
un
de
ye
s,
no
str
ils
an
df
ro
nt
leg
s.
(IT
)
Pil
oe
rec
tio
n(
>
75
%
of
bo
dy
),
fur
ma
tte
da
nd
un
-gr
oo
me
dw
ith
oth
er
sev
ere
sig
ns
of
illn
ess
.P
or
ph
yr
in
cru
ste
da
ro
un
de
ye
s,
no
str
ils
an
df
ro
nt
leg
s.
(IE
)
Inc
isi
on
Sit
e/
Sk
in
No
rm
al
Sm
all
(es
tim
ate
d
<
1c
m)
ser
om
aa
t
inc
isi
on
sit
e
Sk
in
red
bu
tc
lea
na
nd
dr
y.
On
eo
rt
wo
su
tu
res
mi
ssi
ng
bu
ts
kin
sti
ll
ap
po
sed
.
Sk
in
red
,s
wo
lle
n,
bu
td
ry
.
Mi
ssi
ng
su
tu
res
or
wo
un
ds
lig
ht
ly
op
en
bu
t
cle
an
an
dd
ry
Ev
ide
nc
eo
fs
cra
tch
ing
cre
ati
ng
les
ion
th
at
is
ex
po
sin
gd
ee
pe
rt
iss
ue
so
rl
esi
on
<
0.5
cm
Se
ro
ma
aro
un
di
nc
isi
on
sit
e(
1–
2c
m)
Sk
in/
les
ion
op
en
wi
th
we
td
isc
ha
rg
e
(b
loo
d,
pu
s),
sig
ns
of
inf
ec
tio
n.
Ev
ide
nc
eo
fs
cra
tch
ing
cre
ati
ng
les
ion
th
at
is
ex
po
sin
gd
ee
pe
rt
iss
ue
so
rl
esi
on
>
0.5
cm
Sk
in
sev
ere
ly
da
ma
ge
d(
inf
ec
ted
,
ne
cro
tic
,o
pe
nt
om
us
cle
or
bo
ne
).
Ev
ide
nc
eo
fs
ev
ere
sel
f-m
ut
ila
tio
n.
Co
ns
tan
ts
cra
tch
ing
(ev
en
wh
en
dis
tu
rb
ed
)c
rea
tin
gl
esi
on
th
at
is
>
1c
m.
La
rg
es
ero
ma
(>
2m
l).
Im
pla
nt
ex
po
sed
.
De
hy
dr
ati
on
No
rm
al
Mi
ldl
ys
un
ke
ne
ye
s(
ap
pe
ar
>
75
%
op
en
).
Sk
in
ten
t>
2s
(d
ec
rea
se
in
sk
in
ela
sti
cit
y)
rep
res
en
ts
10
–1
5%
de
hy
dr
ati
on
.S
un
ke
n
ey
es
(ap
pe
ar
ha
lf
clo
sed
).
Sk
in
ten
t>
5s
rep
res
en
ts
15
–2
0%
de
hy
dr
ati
on
.C
om
ple
tel
yc
los
ed
or
sev
ere
ly
su
nk
en
ey
es;
tai
lf
ee
ls
sq
ua
re.
Co
ol
to
tou
ch
.(
IT
)
An
im
al
un
res
po
ns
ive
an
dc
old
to
tou
ch
.S
ev
ere
sk
in
ten
t(
>
10
s).
(IE
)
Eli
mi
na
tio
n:
Fe
ce
s
Ur
ine
Bl
ad
de
r
Ur
ine
sca
ld
No
rm
al
So
ft
Sto
ols
Da
ily
pa
ste
-li
ke
fec
es.
Hy
dr
ati
on
no
rm
al.
Bl
oo
dy
ur
ine
.B
lad
de
r
reg
ula
rly
mo
re
th
an
ha
lf
ful
l.
Da
ily
wa
ter
yd
iar
rh
ea
wi
th
oc
ca
sio
na
l
for
me
ds
oft
fec
es.
Sm
all
are
ao
ff
ec
al
sta
ini
ng
aro
un
da
nu
so
rm
ild
ur
ine
sca
ldi
ng
(w
et,
red
dis
h
sk
in)
.H
yd
rat
ion
no
rm
al.
Bl
ad
de
rr
eg
ula
rly
req
uir
es
ex
pr
ess
ion
.
W
ate
ry
dia
rrh
ea
or
inc
rea
sed
ur
ine
ou
tpu
t
res
ult
ing
in
de
hy
dr
ati
on
.
La
rg
ea
rea
of
fec
al
sta
ini
ng
on
fur
or
ur
ine
sca
ldi
ng
(w
et,
red
dis
hs
kin
).
Bl
oo
dy
ur
ine
wi
th
clo
ts;
diffi
cu
lty
ex
pr
ess
ing
bla
dd
er
(IT
)
On
ly
wa
ter
yo
rb
loo
dy
dia
rrh
ea
an
d
inc
rea
sed
ur
ine
ou
tpu
t;
un
ab
le
to
ma
int
ain
hy
dr
ati
on
.
Bl
ad
de
rc
an
no
tb
ee
xp
res
sed
or
bla
dd
er
ru
ptu
red
.S
ev
ere
ur
ine
sca
ld
ex
po
sin
gu
nd
erl
yin
gt
iss
ue
or
as
so
cia
ted
wi
th
sev
ere
sw
ell
ing
.(I
E)
Re
sp
ira
tio
n:
Ra
te
Rh
yth
m
Eff
or
t
(es
pe
cia
lly
for
or
al
ga
va
ge
)
Su
btl
ec
ha
ng
ei
n
rat
eo
r
eff
or
tw
ith
ac
tiv
ity
bu
t
no
rm
al
at
res
t.
Re
gu
lar
rh
yth
m.
Ob
vio
us
ch
an
ge
in
rat
eo
re
ffo
rt
wi
th
ac
tiv
ity
an
da
tr
est
(se
ec
he
st
ex
pa
ns
ion
).
Oc
ca
sio
na
li
rre
gu
lar
rh
yth
m.
Sm
all
am
ou
nt
of
na
sa
ld
isc
ha
rg
eo
r
sn
ee
zin
g.
Re
du
ce
dr
ate
(ea
sy
to
co
un
t)
at
res
ta
nd
wh
en
ac
tiv
e.
Irr
eg
ula
rr
hy
th
m.
Ap
pe
ars
to
req
uir
ee
ffo
rt
(h
ea
db
ob
so
rb
od
ym
ov
es
wi
th
br
ea
th
ing
).
No
isy
br
ea
th
ing
;N
as
al
dis
ch
arg
ea
ffe
cti
ng
br
ea
th
ing
.(
IT
)
Re
du
ce
dr
ate
(R
ats
<
75
bp
m)
.
Irr
eg
ula
rr
hy
th
m.
Inc
rea
sed
eff
or
tt
ob
rea
th
e(
he
ad
bo
bb
ing
)f
or
mo
re
th
an
4h
;G
as
pin
g,
str
ug
gli
ng
to
br
ea
th
,o
pe
nm
ou
th
br
ea
th
ing
.S
kin
cy
an
oti
c(
blu
e).
(IE
)
Au
tot
om
y
Mi
ld
ch
ew
ing
on
toe
s
th
ou
gh
no
los
so
ft
iss
ue
(m
ild
red
ne
ss
or
sw
ell
ing
)
Lo
ss
of
toe
na
ils
on
1o
rm
or
ed
igi
ts,
so
me
ex
po
sed
raw
tis
su
e
Lo
ss
be
yo
nd
1s
tk
nu
ck
le
on
<
2d
igi
ts
Lo
ss
be
yo
nd
1s
tk
nu
ck
le
on
2o
rm
or
e
dig
its
.L
os
so
fa
ny
on
ed
igi
t>
2n
d
kn
uc
kle
.(
IE
)
Pa
in
Fa
cia
lG
rim
ac
e:
Na
rro
w
or
clo
sed
ey
es,
Fla
tte
nin
go
fb
rid
ge
of
no
se,
bu
lge
on
top
of
no
se,
ch
ee
k(
be
tw
ee
n
ey
ea
nd
wh
isk
ers
)b
ulg
e,
ea
rs
ba
ck
or
fla
t,
wh
isk
ers
po
int
ing
ba
ck
or
“st
an
din
go
ut
on
en
d”
.
Ot
he
r:
Mu
scl
et
wi
tch
ing
or
fli
nc
hin
g,
sta
gg
eri
ng
,b
ac
ks
tre
tch
,a
bd
om
ina
lw
rit
hin
go
rp
res
sin
g.
Pe
rsi
ste
nt
sig
ns
of
pa
in
th
at
int
erf
ere
wi
th
no
rm
al
fun
cti
on
so
rc
an
no
tb
e
all
ev
iat
ed
.(
IE
)
An
im
al
Mo
nit
or
ing
Ke
y:
IT
(Im
me
dia
te
tre
atm
en
tr
eq
uir
ed
)a
nd
IE
(Im
me
dia
te
Eu
th
an
as
ia)
.A
sco
re
of
th
ree
in
an
yc
ate
go
ry
or
ac
um
ula
tiv
es
co
re
of
6o
rh
igh
er
res
ult
si
ni
nc
rea
sed
mo
nit
or
ing
an
ds
up
po
rti
ve
ca
re
(e.
g.
su
pp
lem
en
tal
he
at,
su
bc
ut
an
eo
us
flu
ids
,a
dd
iti
on
al
an
alg
esi
ag
el
foo
d
or
foo
dt
rea
ts/
mo
ist
en
ed
pe
lle
ts
on
ca
ge
flo
or
,e
tc.
ba
sed
on
cli
nic
al
sig
ns
).
Str
uc
tu
red
,o
bje
cti
ve
rec
or
din
gs
ys
tem
sc
an
als
ob
eu
sef
ul
in
or
de
rt
oi
de
nt
ify
cli
nic
al
sig
ns
th
at
ma
yi
nd
ica
te
ad
ve
rse
an
im
al
we
lfa
re.
Sy
ste
ms
su
ch
as
th
is
set
ou
tc
lea
ra
cti
on
s(
e.g
.in
cre
as
ed
mo
nit
or
ing
,s
up
po
rti
ve
ca
re,
ve
ter
ina
ry
tre
atm
en
to
re
ut
ha
na
sia
)f
or
an
im
al
ca
re
sta
ff.
E. Lilley, et al. Experimental Neurology 328 (2020) 113273
9
under some regulatory frameworks. Clearly the optimal approach to
balance these issues is to develop and validate training materials that
deliver the learning objectives required for SCI model training without
using animals, as far as is possible. The EWG recommends that such an
approach is evaluated and required resources and materials are de-
signed, developed and freely shared. An online repository, such as Open
Data Commons for Spinal Cord Injury (ODC-SCI; https://scicrunch.org/
odc-sci) could be a good place to store such resources or materials.
Some online materials are available with respect to handling and in-
jecting animals (e.g. http://www.procedureswithcare.org.uk/, https://
flairelearning.com/). Some SCI relevant resources (e.g. surgical models,
behavioural testing and neurophysiology) are available on the JOVE
(Journal of Visualised Experiments) website (Lee et al., 2012; Kathe
et al., 2014; Cheah et al., 2017; Brown and Martinez, 2019).
Recommendation: Consider working with national or international
organisations or funding bodies to help develop/support training op-
portunities for new SCI researchers to develop the necessary skills to
perform SCI models competently and reproducibly.
6.3. Maintaining and disseminating good practice
The EWG intended this report to be used as the basis of discussions
as to how SCI animal models can be developed and refined within a
given research group or establishment, keeping abreast with current
good practice and stimulating ongoing improvement. The EWG re-
commends regular discussion with animal technologists and care staff,
veterinarians and the local ethics or animal care and use committee as
well as with other researchers working in the field. It is also worth
consulting websites of national 3Rs centres e.g. NC3Rs in the UK,
NORECOPA in Norway, ICAR3Rs in Germany and the North American
3Rs Collaborative in the USA. Publications should also include full
details of experimental protocols including any details relevant to im-
proving animal welfare (online in supplementary materials if neces-
sary); attention to reporting standards mentioned earlier (in section
6.1) can help with this.
7. Future directions
7.1. Biomarker measurement
In drug discovery programs, two key pieces of information are
needed regarding the pharmacology of new potential therapies: de-
monstration of target engagement and the free plasma concentration
required to achieve the required target engagement. Where the pro-
posed therapeutic mechanism is well characterised, model systems can
be used that assess activity only on the mechanistic pathway of interest,
and a disease model may not be required. For example, if a potential
drug discovery target is relevant to neurotrauma in general, a nerve
injury that has the potential for a lower welfare burden (e.g. optic nerve
injury) can be used for drug screening purposes. This approach is often
referred to as mechanistic modelling as opposed to disease modelling
(Hunter, 2011). The mechanistic modelling approach to developing
new therapies is obviously easier to apply to diseases in which the
underlying pathophysiological mechanisms are well characterised.
In SCI, the key processes and pathways that underlie neurodegen-
eration, neuroinflammation, resolution and neuroplasticity, which are
presumed but not proven to underlie the prognosis for patients, are
unfortunately not yet adequately understood, despite significant re-
search investment. Currently, SCI research is largely focussed on dis-
ease models with high face validity and mechanistic modelling largely
reserved for target identification studies. There is a need for relevant,
specific, translatable biomarkers of the different aspects of SCI which
could enable pathway driven, mechanistic modelling in drug discovery.
This could drive selection and further development of in vitro or in
silico techniques to contribute to advancements in this field. Although
some interesting work is being done in this important field the EWG
agreed that this should be an area incorporated into future research
(Saadoun and Papadopoulos, 2016; Kwon et al., 2017).
7.2. Bioinformatics and ‘Big Data’
An interesting direction in the field of experimental SCI is the de-
velopment of a worldwide database for translational SCI research,
which will harness the power of analysis of ‘big data’ to better under-
stand the mechanisms underlying recovery across species, thus enhan-
cing the potential of successful clinical translation (Ferguson et al.,
2011; Nielson et al., 2014).
Such an approach has the potential to promote improved experi-
mental design (including randomised block design, blinding and other
measures to reduce bias) and, where appropriate, standardisation of SCI
pre-clinical model selection and deployment. Full standardisation may
be impossible given the inherent complexity and variability of surgical
SCI, but efforts to optimise the translational impact of pre-clinical re-
search should be explored from an ethical perspective, both to reduce
potentially fruitless animal use and to improve patient benefit.
8. Conclusion
This report gives some guidance to help researchers apply the 3Rs to
SCI research, with a focus on practical refinement approaches that can
be used to reduce animal suffering. Applying replacement in SCI re-
search can be challenging at present. However, there is always scope for
applying the Rs of refinement and reduction, which are highly effective
ways to reduce suffering and improve scientific quality. The authors
hope that the recommendations in this document will be used and
further developed and disseminated by researchers working in this
field.
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